This has not been completed in a research capacity, let alone a clinical one.
Yes, you measure quantitative PCR copies of CMV/EBV in the cerebrospinal fluid or you do post-mortem in situ hybridization, it's pretty easy and make sure it regiospecific for the susceptible substructures.
A person born without legs can have pain in their ankle. I am wary to underestimate that relevance to CFS.
The idea of a new grad doing this is hilarious to me: the MCAT is now like half organic chemistry, half "how woke are you?". I know old school docs like this though.
Objective diagnostics in MS allow for better patient cohorts - lesions, objective measurements of optic neuritis, oligoclonal banding. Even beyond that, they properly split the illness even with 1/10th the patients.
It is a pharmaceutical goldmine for endpoints - but lesion size etc. rarely...
Stuart Johnson was a consultant studies that I referenced. He is a neuroscientist at Georgetown. The protocol is here.
The patients were quarantined, diet-controlled, had drug restrictions and I do not see how it would be helpful to know that repeated administrations would decrease cognitive...
They already did in the studies I posted. Blood tests and lumbar punctures after the cognitive testing but before the exercise (regardless whether they published it - the default mode network study had CFS patients but they were not included in the manuscript). You would be able to interpolate...
https://www.nature.com/articles/s41598-017-15383-9
https://bmcneurosci.biomedcentral.com/articles/10.1186/s12868-019-0488-6
They excluded a lot from these papers even though they covered a lot of what you asked. They could be data mining or the results could be irrelevant, it is probably the...
So what this study tells is that healthy controls are more active.
It is one thing to criticize patient/control selection as a semantical issue (to make results generalizable), but is another to criticize the control selection and knowing why the underlying physiology could nullify it.
The owner of the molecule may be pumping its value for resale. One way to do this is a performative and non-substantive open-label study, make a press release and get some buzz to increase its right's of manufacture price and sell it to another entity. This guy is Garry Marshall not Barry...
Sorry for my English - I believe they are recommending that other avenues be pursued outside cytokines.
"CureME is committed to patient participation, and ensures that its research is always informed by and for the benefit of people with ME/CFS. We have contributed to highly significant...
Does anyone from Solve/MECFS and OMF read this?
Get in contact with Harmony Biosciences business development and ask for a donation of product to start a trial, crossover amphetamine crossover placebo.
People that die from oncogenic viral brain tumors do not have any evidence of serological antibodies to their giant brain tumors that make them die.
HHV exists in lymphatics for transmission purposes at best. So do a biopsy of the lymph nodes or a lumbar puncture (you will not get very robust...
The idea of any infection starting CFS's specific fatigue was abandoned rapidly when a few people had an atypical onset and didn't have peripheral antibodies.
This was a problem in other illnesses too, until a few researchers suspected it was impossible for that rapid of an onset to not be...
Study was cohort participatory and not observational and generally reflects who participates in these studies uncompensated. I do not have any comments on it directly other than the context I posited above.
Copied post
Study was cohort participatory and not observational and generally reflects who participates in these studies uncompensated. I do not have any comments on it directly other than the context I posited above.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.